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Abstract: Treatment-related adverse events (AEs) can obfuscate the maintenance of a conventional
schedule of sunitinib in patients with metastatic renal cell carcinoma. Accordingly, alternative
schedules seeking to improve the safety profile of sunitinib have been tested. Recently,
two meta-analyses similarly described improved safety profiles favoring a two weeks on and one
week off (2/1) schedule, but with conflicting results for survival outcomes. Therefore, we conducted
an updated systematic review and meta-analysis, including all recently published studies and using
complementary statistical methods. Endpoints included progression-free survival, overall survival,
and AEs of 15 types. Eleven articles were included in this meta-analysis. Using adjusted findings,
we noted statistically better results in progression-free survival (hazard ratio, 0.58; 95% confidence
interval, 0.39–0.84; p = 0.005), but no difference in overall survival (hazard ratio, 0.66; 95% confidence
interval, 0.42–1.04; p = 0.08). Moreover, the 2/1 schedule was beneficial for reducing the incidence
of several AEs. Conclusively, our meta-analysis suggests that the 2/1 schedule holds promise as
an alternative means of reducing AEs and maintaining patient quality of life. While the survival
outcomes of the 2/1 schedule seem also to be favorable, the level of evidence for this was low, and the
interpretation of these findings should warrant caution. Large scale randomized trials are needed to
support these results.
Keywords: renal cell carcinoma; sunitinib; alternative dosing; survival outcomes; adverse events;
systematic review; meta-analysis
1. Introduction
The therapeutic concept of metastatic renal cell carcinoma (mRCC) has been dramatically changed
through the development of targeted therapies, which result in significant improvement of clinical
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outcomes [1]. Sunitinib is an oral inhibitor of vascular endothelial growth factor (VEGF) receptors
1, 2, and 3 as well as platelet-derived growth factor receptors. Sunitinib is currently used as the first
choice in the treatment of mRCC, and it has been shown to increase progression-free survival (PFS)
when compared to interferon-α. The standard dosing schedule for sunitinib is 50 mg once daily for
four weeks on and two weeks off (4/2). In the original phase III trial, 38% and 32% of patients taking
sunitinib experienced dose interruptions and reductions, respectively, due to secondary toxicity [2].
Treatment-related adverse events (AEs) can make it difficult to maintain the standard dosing schedule
of sunitinib, AEs may cause a decrease in quality of life (QOL) for these patients, as well as an increase
in costs due to concomitant medication or conservative treatment.
Accordingly, some alternative schedules have been tested in an attempt to improve the safety profile
and increase the dose intensity of sunitinib [3–13]. A continuous once daily dosing regimen with 37.5 mg
of sunitinib has been proposed as an alternative [14], although the most often attempted strategy is a two
weeks on and one week off (2/1) schedule. Several researchers have reported the clinical outcomes of the
2/1 schedule, including one phase II randomized controlled trial (RCT) [3,6,8–13,15], however, there has
been no phase III RCT comparing 2/1 and 4/2 schedules of sunitinib. Recently, two meta-analysis
studies have been published on this topic [16,17]. These two studies consistently suggested that
the 2/1 dosing schedule was superior to the 4/2 dosing schedule in terms of treatment-related AEs;
however, they showed conflicting results for survival outcomes. Therefore, in order to compare the
efficacy and safety between the 2/1 and the 4/2 schedules, we performed an updated systematic review
and meta-analysis, including all recently published studies. In addition, the quality of evidence was
assessed using complementary statistical methods for assessing the certainty of the generated evidence.
2. Materials and Methods
2.1. Search Strategy
A literature search of all publications that appeared before August 2019 was performed using
Embase (a biomedical literature database), PubMed, and Cochrane library. In addition, a cross-reference
search of eligible articles was performed to check studies that were not found during the computerized
search. We used combinations of the following MeSH terms and keywords: ‘sunitinib’, ‘renal cell’,
‘cancer’, ‘carcinoma’, ‘schedule’, ‘regimen’, and relevant variants. Conference abstracts were excluded
even if they met eligibility criteria. Only trials published in English were included. The search
produced 648 articles. Two authors (D.Y.C., J.W.K.) independently reviewed the titles and abstracts
based on pre-established inclusion criteria and reviewed identified articles.
2.2. Inclusion Criteria and Study Eligibility
Eligibility of a study was evaluated using the consideration of participants, interventions,
comparators, outcomes, and study design approach (PICOS), and the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We defined the study population as
patients diagnosed with mRCC, and the intervention as administration of sunitinib on a 2/1 schedule
from the beginning of treatment, without any changes to the schedule. The comparator was defined as
patients who had only undergone a 4/2 sunitinib schedule. The outcomes measured were AEs rate,
PFS rate, and overall survival (OS) rate. The following inclusion criteria were used: (1) human subject
research; (2) the baseline characteristics of patients from two groups must be comparable, including
the total number of subjects and values of each index; (3) the comparator group must include patients
with mRCC who had undergone treatment with a 4/2 sunitinib schedule; (4) the study group must
contain patients with mRCC who had undergone treatment with a 2/1 sunitinib schedule; (5) outcome
values reported must include rates of AEs, and/or rates of PFS and OS. In addition, both randomized
and nonrandomized clinical trials were included.
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2.3. Data Extraction
Two authors (D.Y.C., J.W.K.) independently reviewed the included articles and extracted the data
at the trial level for each trial. Any discrepancies in the extracted data between the two reviewers were
resolved through consensus. Extracted data included details on study design, inclusion and exclusion
criteria, whether participants were randomized or nonrandomized, participant demographics and
oncological characteristics, patient treatment characteristics (dosing schedule and median follow-up
period), outcomes measured (PFS, OS, number of AEs, and hazard ratios (HR), 95% confidence intervals
(CI), and p-values). The primary endpoint was the incidence of AEs. AEs were graded according
to the National Cancer Institute—Common Terminology Criteria for Adverse Events, version 3.0 or
4.0. The incidences of overall and high-grade (grade 3 or higher) AEs were investigated separately.
Secondary endpoints were the oncological outcomes, PFS and OS. Progression was defined as the
progression of distant metastasis based on response evaluation criteria in solid tumors (RECIST)
version 1.0 or 1.1 after initiation of sunitinib. OS was defined as the interval between the initiation of
sunitinib and death due to mRCC or any other cause.
2.4. Study Quality Assessments
After the final group of articles was agreed upon, two authors (D.Y.C., J.W.K.) independently
examined the quality using the Cochrane risk of bias tool and the Newcastle–Ottawa Scale (NOS).
The Cochrane risk of bias tool for quality assessments of RCTs was recommended by the Cochrane
Handbook for Systematic Reviews of Interventions [18]. The Cochrane risk of bias tool for RCTs
is a seven-item list, which is designed to assess the following: (1) random sequence generation,
(2) allocation concealment, (3) blinding of participants and personnel, (4) blinding of outcome
assessment, (5) incomplete outcome data addressed, (6) selective reporting, and (7) other potential biases.
Each item is further divided into three levels: high, unclear, and low risk of bias. Additionally, quality
evaluation of included nonrandomized studies was performed according to the Newcastle–Ottawa
Scale (NOS) [19]. The three major assessment categories of the NOS include selection, comparability,
and exposure. A study can be given a rating of up to nine stars, and a final score of six stars or more
is considered high quality. We assessed the quality of the generated evidence using the Grading
of Recommendations, Assessments, Developments, and Evaluation (GRADE) system [20]. GRADE
is used to systematically approach the evaluation and strength of recommendations. It consists of
domains for methodology evaluation, accuracy of results, consistency of results, immediacy, and risk
of publication bias. Based on these five criteria, the quality of evidence was rated as belonging to one
of four levels (high, moderate, low, and very low).
2.5. Statistical Analysis
The effects of dosing schedules of sunitinib on oncological outcomes (PFS and OS) were measured
using hazard ratios (HR). Log HR values were obtained directly from the papers reporting HR point
estimates and CI, and the standard errors of log-HR were calculated using published CI [21]. Although
some trials reported Kaplan–Meier log-rank p-values, they omitted HR or 95% CI, or both. In these
cases, we estimated HR and 95% CI using p-values, number of total events, and number of participants
that were randomized to each arm [22]. Also, for each study we assessed the risk ratio (RR) and the
corresponding 95% CI of incidence of AEs. Pooled HR or RR with 95% CI indicated the effects according
to dosing schedules on OS, PFS, and AEs. Estimates were then combined using a random effects
model [23]. Chi square heterogeneity tests were used to test for statistical heterogeneity between trials.
The I2 statistic was calculated to measure discrepancies between clinical trials. A Cochran Q statistic
p-value < 0.05 or I2 statistic > 50% was used to indicate statistically significant heterogeneity between
trials [24]. If 10 studies or more that investigated a particular outcome were included, the use of funnel
plots to assess small study effects was planned. However, fewer than 10 studies qualified for this review.
A sensitivity analysis was performed by assessing the stability of results when each included study was
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sequentially excluded. Review Manager v.5.3 (2008; Nordic Cochrane Center, Cochrane Collaboration,
Copenhagen, Denmark) was used for performing the meta-analysis. All p-values were two-sided,
and except for the test of discrepancy, a p-value < 0.05 was considered statistically significant.
3. Results
3.1. Systematic Review Process
The results for the PRISMA flow diagram are presented in Figure 1. The initial database search
found 648 studies (363 in PubMed, 242 in EMBASE, and 43 in the Cochrane library); among them,
242 studies remained after duplicates were removed. The titles and abstracts were then examined.
As a result of this review, 210 articles were excluded. Subsequently, analysis of the full text articles
was performed based on pre-established inclusion criteria. Finally, 11 studies with a total of 1012
patients were included. Information on the included studies is presented in Table 1. Both retrospective
observational studies and one RCT were included. Of the 11 studies, 1 was an RCT and the remaining
10 were retrospective studies. The RCT was conducted in South Korea. Of the retrospective studies,
four were conducted in Japan, two in China, one in USA, one in Egypt, one in Canada, and one was
a multicenter study that included patients from several European countries. All ten trials enrolled
patients diagnosed with mRCC who had undergone sunitinib treatment according to either 2/1 or 4/2
dosing schedules.Cancers 2019, 11,  5 of 18 
 
 
Figure 1. Flowchart of Preferred Reporting Items for Systematic Reviews and Meta-analysis 
(PRISMA). 
Figure 1. Flowchart of Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA).
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Table 1. Characteristics of eligible studies.
Author(s)
(Year) Country
Study
Design Study Summary
1. Interval of Imaging Studies
2. Tumor Response Evaluation
3. Adverse Events Evaluation
Schedule No. ofPatients
Follow up
(Months)
PFS
(Months,
IQR)
OS
(Months,
IQR)
Atkinson et
al. (2014) USA Retrospective
Comparisons of oncological outcomes and incidence of
adverse events between two groups: 2/1 and 4/2, 4/2 to
2/1 switch
1. NR
2. RECIST v.1.1
3. NCI CTCAE v.4.0
2/1 dosing 24
NR
Median 11.6
(5.8–18.3)
Median 27.7
(21.2–NE)
4/2 dosing 98 Median 4.3(3.4–6.4)
Median 17.7
(10.8–22.2)
Kondo et al.
(2014) Japan Retrospective
Comparisons of oncological outcomes and incidence of
adverse events between two groups: 2/1 and 4/2
1. CT every 6–12 weeks
2. RECIST v.1.1
3. NCI CTCAE v.4.0
2/1 dosing 26 Mean 11.9 ± 8.1(range 2.6–31.6)
Median 18.4
(NR)
NR
4/2 dosing 22 Mean 13.3 ± 10.1(range 1.5–39.1)
Median 9.1
(NR)
Najjar et al.
(2014) Japan Retrospective
Comparisons of incidence of adverse events between
two groups: 2/1 and 4/2
1. RECIST v.1.1
2. NCI CTCAE v.4.0
2/1 dosing 30 Median 11.9(range 0.9–73.3)
NR NR
4/2 dosing 30 Median 12.6(range 1.2–62)
Bracarda et
al. (2015) Europe Retrospective
Comparisons of oncological outcomes and incidence of
adverse events among three groups: 2/1, 4/2, and 4/2 to
2/1 switch
1. CT or MRI every 12 ± 1 weeks
2. NR
3. NCI CTCAE v.3.0 or v.4.0
2/1 dosing 41 Median 7.8(IQR 5.8–22.4)
NR NR
4/2 dosing 208 Median 4.3(IQR 2.0–12.0)
Lee et al.
(2015)
South
Korea
Randomized
controlled
Comparisons of oncological outcomes and incidence of
adverse events between two groups: 2/1 and 4/2
1. CT every 12 weeks
2. RECIST v.1.0
3. NCI CTCAE v.3.0 or v.4.0
2/1 dosing 38 Median 30.0
(IQR 19.5–53.6)
Median 12.1
(4.0–25.3)
Median 30.5
(18.9–42.0)
4/2 dosing 36 Median 10.1(7.5–12.7)
Median 28.4
(11.3–45.4)
Miyake et al.
(2015) Japan Retrospective
Comparisons of incidence of adverse events between
two groups: 2/1 and 4/2
1. CT every 12 weeks
2. RECIST v.1.0
3. NCI CTCAE v.3.0
2/1 dosing 45 Median 3.4(range 1.3–19.7) NR NR
4/2 dosing 45 Median 8.9(range 2.3–21.4)
Pan et al.
(2015)
China Retrospective
Comparisons of oncological outcomes and incidence of
adverse events among three groups: 2/1, 4/2, and 4/2 to
2/1 switch
1. NR
2. RECIST v.1.1
3. NCI CTCAE v.4.0
2/1 dosing 32
Median 1.5
years (range
1.0–2.2)
Median 11.2
(NR) NR
4/2 dosing 50
Median 1.9
years (range
1.3–2.7)
Median 9.5
(NR) NR
El Din (2017) Egypt Retrospective
Comparisons of oncological outcomes and incidence of
adverse events between two groups: 2/1 and 4/2
1. CT or MRI every 18 weeks
2. NR
3. NCI CTCAE v.4.0
2/1 dosing 26 Median 23(range 3–43)
Median 17
(2–43)
Median 24
(2–42)
4/2 dosing 30 Median 24(range 2–42)
Median 15
(1–42)
Median 23
(3–43)
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Table 1. Cont.
Author(s)
(Year) Country
Study
Design Study Summary
1. Interval of Imaging Studies
2. Tumor Response Evaluation
3. Adverse Events Evaluation
Schedule No. ofPatients
Follow up
(Months)
PFS
(Months,
IQR)
OS
(Months,
IQR)
Suo et al.
(2017) Canada Retrospective
Comparisons of oncological outcomes and incidence of
adverse events among three groups: 2/1, 4/2, 2/1
modified dosing (37.5 mg, 25 mg, or 12.5 mg) and
continuous dosing (37.5 mg, 25 mg, or 12.5 mg)
1. NR
2. RECIST
3. NR
2/1 dosing 9
NR
Median 6.0
(NR)
Median 23.1
(NR)
4/2 dosing 59 Median 3.0(NR)
Median 11.2
(NR)
Miyake et al.
(2018) Japan Retrospective
Comparisons of oncological outcomes and incidence of
adverse events among three groups: 2/1, 4/2, and 4/2 to
2/1 switch
1. CT every 6–12 weeks
2. RECIST v.1.1
3. NCI CTCAE v.3.0
2/1 dosing 47
NR
Median 13.8
(NR)
Median 39.2
(NR)
4/2 dosing 62 Median 6.3(NR)
Median 30.8
(NR)
Zhang et al.
(2018) China Retrospective
Comparisons of oncological outcomes and incidence of
adverse events among three groups: 2/1, 4/2, and 4/2 to
2/1 switch
1. NR
2. RECIST v.1.1
3. NCI CTCAE v.4.0
2/1 dosing 24
Median 37
Median 11
(NR)
Median 28
(NR)
4/2 dosing 30 Median 12.5(NR)
Median 21
(NR)
CT, computed tomography; IQR, interquartile range; MRI, magnetic resonance imaging; NE, not estimable; NR, not reported; NCI CTCAE, National Cancer Institute Common Terminology
Criteria for Adverse Events version; OS, overall survival; PFS, progression free survival; RECIST, The Response Evaluation Criteria in Solid Tumor; US, ultrasonography.
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3.2. Quality Assessment
The results of the quality assessment based on the Cochrane risk of bias tool of the one included
RCT are shown in Table 2A. In the RCT, there were two main sources of bias. The first was an unblinded
study design (of open label nature), which could have led to bias because patients may switch from
one arm to the other based on personal preferences. The second source of probable bias was that,
in this study, the priority was selecting the schedule that had a higher failure-free survival rate at
six months; therefore, other results (progression-free survival and overall survival) may have been
influenced. Results of the quality assessment using NOS for the included nonrandomized studies are
shown in Table 2B. Six out of the nine studies received a score of 6 points (indicating high quality).
The investigation by Suo et al., Pan et al., and Zhang et al. received a score of 5 points due to insufficient
information in the paper, which did not allow reviewers to determine whether the same method of
ascertainment had been used in cases and controls.
3.3. Oncological Outcomes; Progression-Free Survival and Overall Survival
A total of seven nonrandomized studies [3,8–13] were included in a comparison of oncological
outcomes according to dosing schedules. However, two studies [3,8] did not report an analysis of OS;
therefore, OS was analyzed using data from the other five studies. One RCT by Lee at al. [6] was not
included in the meta-analysis for survival outcomes due to the heterogeneity in study design. PFS and
OS analysis were performed in two ways, using either unadjusted or adjusted HRs.
In the analysis using unadjusted HRs, meta-analysis revealed an overall HR of 0.65 for PFS in
patients receiving the 2/1 dosing schedule (p = 0.0003; 95% CI, 0.51–0.82). Heterogeneity was found
across studies (Cochran Q statistic, p = 0.03; I2 statistic, 56%), and an overall HR of 0.70 was revealed
for OS in patients receiving the 2/1 dosing schedule (p = 0.01; 95% CI, 0.53–0.93). No heterogeneity
across studies was found (Cochran Q statistic, p = 0.21; I2 statistic, 32%) (Figure 2).
In the analysis using adjusted HRs, meta-analysis revealed an overall HR of 0.58 for PFS in patients
receiving the 2/1 dosing schedule (p = 0.005; 95% CI, 0.39–0.84). No heterogeneity was found across
studies (Cochran Q statistic, p = 0.22; I2 statistic, 33%). Finally, it revealed an overall HR of 0.66 for OS
in patients receiving the 2/1 dosing schedule (p = 0.08; 95% CI, 0.42–1.04). No heterogeneity across
studies was found (Cochran Q statistic, p = 0.83; I2 statistic, 0%) (Figure 2).
The assessment of the quality of evidence of each comparison using the GRADE approach is
shown in Table 3. Certainty was “very low” in all comparisons.
3.4. Incidence of Adverse Events
Nine studies [3–9,11,12] were included for assessment of AE incidence. Both overall and high-grade
incidence of 15 AEs were investigated (Table 4). Fifteen AEs were classified into three categories;
laboratory AEs (hypothyroidism, leukopenia, anemia, thrombocytopenia, and liver dysfunction),
gastrointestinal AEs (anorexia, nausea, vomiting, diarrhea, dysgeusia), and others (hand–foot syndrome,
hypertension, fatigue, stomatitis, skin color change). A meta-analysis was performed for the comparison
of AE incidence according to dosing schedules. In the 2/1 sunitinib dosing schedule patients, there were
statistically significant reductions in both overall and high-grade incidence of fatigue, hypertension,
stomatitis, leukopenia, and skin color change. In addition, overall incidence of diarrhea, hand–foot
syndrome, hypothyroidism, and dysgeusia significantly decreased in the 2/1 schedule patients. Finally,
high-grade incidence of thrombocytopenia was significantly lower in patients receiving the 2/1 dosing
schedule compared to those receiving the 4/2 schedule (Tables 5 and 6).
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Table 2. Results of quality assessment by the Cochrane risk of bias tool (A) and Newcastle–Ottawa Scale (B).
A. Quality assessment of a randomized controlled trial
Author(s) (Year)
Random Sequence
Generation
(Selection Bias)
Allocation
Concealment
(Selection Bias)
Blinding of
Participants and
Personnel
(Performance Bias)
Blinding of
Outcome
Assessment
(Detection Bias)
Incomplete Outcome Data
Addressed (Attrition Bias)
Selective Reporting (Reporting
Bias) Other Bias
Lee et al. (2015) Low risk Low risk High risk High risk Low risk Low risk Unclear
B. Quality assessment of nonrandomized studies
Author(s) (Year)
Selection (4) Comparability(2) Exposure (3) Total score
Adequate
Definition
of Cases
Representativeness
of Cases Selection of Controls
Definition of
Controls
Control for
Important
Factor or
Additional
Factor
Ascertainment
of Exposure
Same Method of
Ascertainment for
Cases and
Controls
Non-Response
Rate
Atkinson et al. (2014) 1 1 0 0 2 1 1 0 6
Kondo et al. (2014) 1 1 0 0 2 1 1 0 6
Najjar et al. (2014) 1 1 0 0 2 1 1 0 6
Bracarda et al. (2015) 1 1 0 0 2 1 1 0 6
Miyake et al. (2015) 1 1 0 0 2 1 1 0 6
Pan et al. (2015) 1 1 0 0 2 1 0 0 5
El Din (2017) 1 1 0 0 2 1 1 0 6
Suo et al. (2017) 1 1 0 0 2 1 0 0 5
Miyake et al. (2018) 1 1 0 0 2 1 1 0 6
Zhang et al. (2018) 1 1 0 0 2 1 0 0 5
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Table 3. Results of the GRADE (Grading of Recommendations, Assessments, Developments, and Evaluation) quality assessment of direct evidence of each comparison.
No. of Studies Study Design Risk of Bios Inconsistency Indirectness Imprecision
Other
Consideration
No. of Patients
Effect
Overall
Quality of
Evidence
2/1
Schedule
4/2
Schedule
1. Progression-free survival
7 Unadjusted observational studies not serious not serious not serious Serious * none 188 351 HR 0.66 (0.54–0.82) Very low
4 Adjusted observational studies not serious not serious not serious Serious ** none 83 209 HR 0.58 (0.39–0.84) Very low
2. Overall survival
5 Unadjusted observational studies not serious not serious not serious Serious * none 130 279 HR 0.75 (0.57–0.99) Very low
3 Adjusted observational studies not serious not serious not serious Serious ** none 57 187 HR 0.66 (0.42–1.04) Very low
*: Apply to unadjusted values; **: Total number of participants is small.
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Table 4. Summary of adverse events investigated in the current study.
Study
(year)
Schedule No. of
Patients
Complication (No.)
Hypo-
Thyroidism Leukopenia Anemia
Thrombo-
cytopenia
Liver
Dysfunction Anorexia Nausea Vomiting Diarrhea Dysgeusia HFS HTN Fatigue Stomatitis
Skin Color
Change
Al * HG Al * HG* All HG All
HG
* All HG All HG All HG All HG
All
* HG
All
* HG
All
* HG
All
*
HG
*
All
*
HG
*
All
*
HG
*
All
* HG
Kondo et
al. (2014)
2/1 26 10 0 22 5 20 3 24 5 18 0 11 1 NR NR NR NR 9 0 6 0 15 0 16 0 19 1 10 0 NR NR
4/2 22 13 0 18 1 19 1 19 6 16 0 14 1 NR NR NR NR 16 1 10 0 19 2 17 0 19 1 13 0 NR NR
Najjar et al.
(2014)
2/1 30 13 0 1 1 NR NR 2 0 NR NR 2 1 2 1 NR NR 11 1 NR NR 5 0 8 2 16 2 3 0 NR NR
4/2 30 11 2 6 3 NR NR 6 3 NR NR 7 2 6 2 NR NR 12 6 NR NR 15 8 8 6 21 11 6 2 NR NR
Bracarda et
al. (2015)
2/1 41 11 1 NR NR NR NR 10 0 NR NR 6 2 8 1 1 0 2 5 7 0 15 2 8 1 26 2 14 1 NR NR
4/2 208 77 3 NR NR NR NR 69 16 NR NR 54 5 63 6 18 1 87 8 68 1 116 21 95 19 155 21 127 14 NR NR
Lee et al.
(2015)
2/1 38 17 0 14 4 27 5 27 9 9 0 21 0 12 0 5 0 14 0 NR NR 26 7 21 9 22 1 27 1 13 0
4/2 36 13 0 22 10 26 3 28 8 11 0 18 0 9 0 6 0 5 1 NR NR 27 13 26 12 30 2 31 4 20 0
Miyake et
al. (2015)
2/1 45 20 0 33 3 26 3 41 13 NR NR NR NR NR NR NR NR 16 0 10 0 15 1 16 1 13 4 11 0 19 0
4/2 45 28 1 36 8 28 4 44 23 NR NR NR NR NR NR NR NR 27 1 13 0 25 5 25 5 23 8 13 0 26 0
Pan et al.
(2015)
2/1 32 19 1 8 3 3 1 8 2 NR NR NR NR NR NR NR NR 10 2 NR NR 15 2 16 1 16 1 9 1 NR NR
4/2 50 28 2 33 8 15 2 18 7 NR NR NR NR NR NR NR NR 32 7 NR NR 42 5 25 4 43 5 23 1 NR NR
El Din
(2017)
2/1 26 9 1 10 1 11 1 4 0 2 0 NR NR
Nausea and
vomiting combine
number
3 NR NR NR 9 0 6 1 10 1 2 1 3 NR
4/2 30 12 4 15 1 11 3 13 3 3 2 NR NR NR NR NR NR 11 NR NR NR 21 6 15 4 21 8 11 6 4 NR
Miyake et
al. (2018)
2/1 47 23 0 34 4 25 5 43 4 20 0 NR NR NR NR NR NR 20 0 NR NR 21 5 17 2 14 5 NR NR 20 0
4/2 62 40 2 50 7 42 6 61 17 34 0 NR NR NR NR NR NR 40 2 NR NR 34 6 37 5 42 11 NR NR 38 0
Zhang et al.
(2018)
2/1 24 9 0 11 2 6 1 8 2 8 2 5 0 NR NR NR NR 7 1 NR NR 10 5 4 2 10 3 7 1 4 0
4/2 30 17 2 17 9 16 2 16 2 8 1 12 1 NR NR NR NR 11 4 NR NR 15 3 12 4 17 7 11 4 6 1
* Statistically significant value; Reference value; 4/2 dosing. HFS, hand–foot syndrome; HG, high-grade; HTN, hypertension; NR, not reported.
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Table 5. Meta-analysis of all grade adverse events according to dosing schedules.
Adverse Events No.Studies
Dosing
Schedule
No. of
Patients
RR p-Value I2 (%) pH-Value
(95% CI)
Laboratory abnormalities
Hypothyroidism * 9
2/1 309 0.84
(0.72–0.99) 0.04 0 0.534/2 513
Leukopenia * 8
2/1 268 0.79
(0.63–0.99) 0.04 60 0.014/2 205
Anemia 7
2/1 238 0.86
(0.72–1.03) 0.10 27 0.224/2 275
Thrombocytopenia 9
2/1 309 0.89
(0.77–1.03) 0.11 62 0.0074/2 513
Liver dysfunction 5
2/1 161 0.88
(0.70–1.12) 0.31 0 0.844/2 180
Gastrointestinal adverse events
Anorexia 5
2/1 159 0.70
(0.47–1.04) 0.08 38 0.174/2 326
Nausea 3
2/1 109 0.77
(0.42–1.45) 0.41 38 0.24/2 274
Vomiting 2
2/1 79 0.62
(0.24–1.62) 0.33 0 04/2 244
Diarrhea * 8
2/1 309 0.62
(0.44–0.89) 0.010 62 0.0074/2 513
Dysgeusia * 3
2/1 112 0.6
(0.39–0.92) 0.02 0 0.684/2 275
Other adverse events
Hand–foot
syndrome * 9
2/1 309 0.68
(0.58–0.81) <0.00001 25 0.224/2 513
Hypertension * 9
2/1 309 0.70
(0.58–0.84) 0.0002 16 0.304/2 513
Fatigue * 9
2/1 309 0.69
(0.60–0.81) <0.00001 29 0.194/2 513
Stomatitis * 8
2/1 262 0.70
(0.57–0.86) 0.0006 10 0.354/2 451
Skin color change * 4
2/1 180 0.70
(0.55–0.89) 0.004 0 0.984/2 203
* Statistically significant value; Reference value; 4/2 dosing, N.A, not available; RR, risk ratio.
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Table 6. Meta-analysis of high-grade adverse events according to dosing schedules.
Adverse Events No.Studies
Dosing
Schedule
No. of
Patients
RR p-Value I2 (%) pH-Value
(95% CI)
Laboratory abnormalities
Hypothyroidism 9
2/1 309 0.46
(0.17–1.23) 0.12 0 0.884/2 513
Leukopenia * 8
2/1 268 0.53
(0.32–0.87) 0.01 0 0.524/2 305
Anemia 7
2/1 238 1.02
(0.55–1.90) 0.95 0 0.904/2 275
Thrombocytopenia * 9
2/1 309 0.58
(0.40–0.83) 0.003 0 0.524/2 513
Liver dysfunction 5
2/1 161 0.91
(0.09–9.42) 0.94 35 0.214/2 180
Gastrointestinal adverse events
Anorexia 5
2/1 159 1.05
(0.34–3.19) 0.93 0 0.74/2 326
Nausea 3
2/1 109 0.67
(0.14–1.45) 0.41 38 0.24/2 274
Vomiting 2
2/1 79 1.66
(0.07–40.02) 0.76 N.A4/2 244
Diarrhea 8
2/1 283 0.52
(0.19–1.41) 0.20 42 0.104/2 483
Dysgeusia 3
2/1 112 1.66
(0.07.40.02) 0.76 N.A4/2 275
Other adverse events
Hand–foot
syndrome 9
2/1 309 0.55
(0.29–1.02) 0.06 30 0.184/2 513
Hypertension * 9
2/1 309 0.51
(0.31–0.83) 0.008 0 0.904/2 513
Fatigue * 9
2/1 309 0.43
(0.26–0.70) 0.0007 0 0.894/2 513
Stomatitis * 8
2/1 262 0.32
(0.13–0.81) 0.02 0 0.894/2 451
Skin color change 4
2/1 154 0.41
(0.02–9.71) 0.58 N.A4/2 173
* Statistically significant value; Reference value; 4/2 dosing. N.A, Not available; RR, Risk ratio.
4. Discussion
Our updated meta-analysis revealed that a sunitinib 2/1 schedule may improve oncological
outcomes and safety profiles, compared to a conventional 4/2 schedule, in patients with mRCC. In terms
of safety profiles, two meta-analysis [16,17] comparing the efficacy and safety between the sunitinib 2/1
and 4/2 schedules showed similar outcomes advocating the sunitinib 2/1 schedule, and our results
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are also consistent with their findings. However, the results for survival outcomes are conflicting.
Chen et al. enrolled three studies for analyzing survival outcomes, and they concluded that there was
no difference in PFS and OS between the 2/1 and 4/2 schedules [16]. However, Sun et al. included five
studies for survival analysis, and among them, four studies were selected for PFS analysis, and another
combination of four studies was used for OS analysis [17]. They indicated that both PFS and OS
outcomes were significantly improved with the 2/1 schedule, compared to the 4/2 schedule. In our
analysis, the 2/1 schedule showed significantly better PFS outcomes when using both unadjusted
HRs from seven studies and adjusted HRs from four studies. OS outcomes were also better with the
2/1 schedule when applying unadjusted HRs from five studies, while there was no difference in OS
outcomes between two schedules when using adjusted HRs from three studies.
These contradictory results were mainly derived from differences in the included studies,
and incorporating more recently published studies, our study included more studies than previous
meta-analyses. In addition, we excluded several studies included in previous meta-analyses, because
those studies enrolled patients who underwent a schedule switch or another alternative schedules
in the 2/1 schedule arm. Sun et al.’s meta-analysis included one phase II RCT in addition to other
observational studies, although it is generally recommended that RCT and nonrandomized studies
should not be combined in meta-analyses because it can result in increased heterogeneity [25]. Moreover,
the previous studies used a mixture of unadjusted and adjusted results in the meta-analysis, while we
pooled unadjusted and adjusted results separately. An unadjusted finding is the bivariate relationship
between an independent and dependent variable that does not control for covariates or confounders.
In cohort studies, unadjusted findings are sometimes presented, but they are generally recognized
as having high potential for bias due to confounding. Therefore, for these types of studies, adjusted
findings are usually preferred for meta-analysis [26]. In addition, we believe that this conflicting OS
result may depend not only on statistical limitations, but also on the response to the drugs following
sunitinib, such as axitinib, cabozantinib, and immune checkpoint inhibitors [27,28]. The currently
included studies did not specify drug schedules after sunitinib, thus it is difficult to investigate adequate
drug sequencing after sunitinib. Additional research on this topic is needed. We also provided the
quality of evidence for the synthesized outcome by applying the GRADE approach, and the level of
evidence for all comparisons was very low, owing to the nature of retrospectively designed studies
and a small number patients—very low quality means very little confidence in the effect estimate,
thus careful interpretation is required. Our meta-analysis demonstrated a positive benefit of the 2/1
dosing schedule in terms of various kinds of AEs. Of the 15 AEs analyzed, the overall or high-grade
incidence of 10 AEs was significantly reduced when using the 2/1 schedule. In particular, the 2/1
dosing schedule was characterized by a decrease in fatigue, stomatitis, diarrhea, hand–foot syndrome,
and dysgeusia, which directly affect the QOL of the patients [29]. Fatigue, especially, is known to
have a significant impact on QOL [30]. In our results, both overall and high-grade fatigue decreased
in patients treated with the 2/1 sunitinib dosing schedule. Therefore, this alternative schedule may
provide a great advantage for patient QOL. In addition, in a study by Houk et al., side effects such as
hypertension and hypothyroidism, which require the use of additional drugs and tests, were found to
be decreased in patients on the 2/1 schedule [31]. This could lead to a reduction in medical costs for
patients receiving sunitinib treatment. In addition, a reduction in hematologic side effects, such as
thrombocytopenia and leukocytopenia, may decrease the need for dose reduction or discontinuation.
Some studies have reported a higher incidence of AEs in patients receiving sunitinib when compared to
the incidence of AEs in patients receiving both pazopanib and sunitinib, which are also first choices of
treatment for mRCC [32,33]. In addition, several studies have reported that dose-adjustment according
to the individual is effective [34–36]. Although the 2/1 schedule may be a way to maintain more drugs
because of fewer AEs compared to the 4/2 schedule, it is important to adjust the concentration of the
drug appropriately according to the condition of the patient rather than a uniform schedule.
Lee et al. conducted a phase II RCT comparing the efficacy and safety between the 2/1 and 4/2
schedules, and demonstrated that the sunitinib 2/1 schedule was associated with less toxicity and
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higher failure-free survival at six months than a 4/2 schedule, without compromising efficacy in terms
of objective response rate and time to progression [6]. Another phase II clinical trial evaluating the
stability of the 2/1 dosing schedule was recently published [15]. Although this study did not directly
compare the results of the 2/1 schedule with the conventional 4/2 schedule, the oncological outcomes
were similar to the outcomes of previously conducted conventional schedule studies. It also found
a decrease in the incidence of some AEs, and a decrease in the number of patients requiring dose
reduction. Jonasch et al. reported a decrease in dose reduction rates and a reduction in the incidence
of AEs above grade 3 that favorably compared with findings from a phase II, COMPARZ study [15].
Although there has been no phase III RCT on this issue, the above-mentioned phase II clinical trials
suggest that the 2/1 sunitinib schedule is associated with less toxicity than the 4/2 schedule without
compromising oncological efficacy. In our meta-analysis, additional evidence was synthesized from
nonrandomized studies, supporting the efficacy and safety of the 2/1 sunitinib schedule.
Our study had several limitations. First, the most included studies had retrospective designs that
could not avoid inevitable limitations, such as selection bias. The small number of studies and sample
size may affect the overall data quality. Second, the number of included studies in the present analysis
was small. Finally, some of the studies in our review did not provide accurate HR and 95% CI for
PFS and OS. Therefore, the estimates obtained using Kaplan–Meier curves were likely to have had
errors. Also, about half of the studies did not provide adjusted HRs for PFS and OS throughout the
multivariate analysis, so the number of studies was limited when the adjusted results were pooled for
survival analysis. Therefore, well-designed RCTs should be conducted to overcome these limitations.
Despite these limitations, our study has several strengths. Compared to previous meta-analyses,
we updated the included studies with recently published literature, and extracted the data from the
more strictly selected studies. In addition, we followed the general recommendations for meta-analysis
from nonrandomized studies to avoid methodological flaws.
5. Conclusions
Our meta-analysis suggests that an alternative 2/1 sunitinib dosing schedule may have better
PFS than the conventional 4/2 sunitinib schedule. However, its level of evidence was very low,
so the interpretation of this result should be cautious. Moreover, the 2/1 schedule was beneficial
for reducing the incidence of AEs. Accordingly, the 2/1 sunitinib dosing schedule holds promise as
an alternative means of reducing AEs, maintaining patient QOL and prolonging treatment. We also
believe that prospective large-scale studies of a 2/1 alternative schedule that demonstrate these
advantages are needed.
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